AIMS/HYPOTHESIS: The genetic engineering of pancreatic beta cells could be a powerful tool for examining the role of key genes in the cause and treatment of diabetes. Here we performed a comparative study of the ability of single-stranded (ss) adeno-associated viral vectors (AAV) of serotypes 6, 8 and 9 to transduce the pancreas in vivo. METHODS: AAV6, AAV8 and AAV9 vectors encoding marker genes were delivered to the pancreas via intraductal or systemic administration. Transduced cells were analysed by immunostaining. AAV9 vectors encoding hepatocyte growth factor (HGF) were delivered intraductally to a transgenic mouse model of type 1 diabetes and glycaemia was monitored. RESULTS: AAV6, AAV8 and AAV9 mediated efficient and long-term transduction of beta cells, with AAV6 and AAV8 showing the highest efficiency. However, alpha cells were poorly transduced. Acinar cells were transduced by the three serotypes tested and ductal cells only by AAV6. In addition, intraductal delivery resulted in higher AAV-mediated transduction of the pancreas than did systemic administration. As proof of concept, intraductal delivery of AAV9 vectors encoding for the beta cell anti-apoptotic and mitogenic HGF preserved beta cell mass, diminished lymphocytic infiltration of the islets and protected mice from autoimmune diabetes. CONCLUSIONS/ INTERPRETATION: Intraductal administration of AAV6, AAV8 and AAV9 is an efficient way to genetically manipulate the pancreas in vivo. This technology may prove useful in the study of islet physiopathology and in assessment of new gene therapy approaches designed to regenerate beta cell mass during diabetes.
AIMS/HYPOTHESIS: The genetic engineering of pancreatic beta cells could be a powerful tool for examining the role of key genes in the cause and treatment of diabetes. Here we performed a comparative study of the ability of single-stranded (ss) adeno-associated viral vectors (AAV) of serotypes 6, 8 and 9 to transduce the pancreas in vivo. METHODS: AAV6, AAV8 and AAV9 vectors encoding marker genes were delivered to the pancreas via intraductal or systemic administration. Transduced cells were analysed by immunostaining. AAV9 vectors encoding hepatocyte growth factor (HGF) were delivered intraductally to a transgenic mouse model of type 1 diabetes and glycaemia was monitored. RESULTS: AAV6, AAV8 and AAV9 mediated efficient and long-term transduction of beta cells, with AAV6 and AAV8 showing the highest efficiency. However, alpha cells were poorly transduced. Acinar cells were transduced by the three serotypes tested and ductal cells only by AAV6. In addition, intraductal delivery resulted in higher AAV-mediated transduction of the pancreas than did systemic administration. As proof of concept, intraductal delivery of AAV9 vectors encoding for the beta cell anti-apoptotic and mitogenic HGF preserved beta cell mass, diminished lymphocytic infiltration of the islets and protected mice from autoimmune diabetes. CONCLUSIONS/ INTERPRETATION: Intraductal administration of AAV6, AAV8 and AAV9 is an efficient way to genetically manipulate the pancreas in vivo. This technology may prove useful in the study of islet physiopathology and in assessment of new gene therapy approaches designed to regenerate beta cell mass during diabetes.
Authors: Eduard Ayuso; Miguel Chillón; Félix García; Judith Agudo; Anna Andaluz; Ana Carretero; Mercè Monfar; Marta Moya; Joel Montané; Pedro J Otaegui; Fàtima Bosch Journal: Mol Ther Date: 2005-12-05 Impact factor: 11.454
Authors: Patrick Collombat; Xiaobo Xu; Philippe Ravassard; Beatriz Sosa-Pineda; Sébastien Dussaud; Nils Billestrup; Ole D Madsen; Palle Serup; Harry Heimberg; Ahmed Mansouri Journal: Cell Date: 2009-08-07 Impact factor: 41.582
Authors: Juan Carlos Lopez-Talavera; Adolfo Garcia-Ocaña; Ian Sipula; Karen K Takane; Irene Cozar-Castellano; Andrew F Stewart Journal: Endocrinology Date: 2003-10-09 Impact factor: 4.736
Authors: Jose Mellado-Gil; Taylor C Rosa; Cem Demirci; Jose A Gonzalez-Pertusa; Silvia Velazquez-Garcia; Sara Ernst; Shelley Valle; Rupangi C Vasavada; Andrew F Stewart; Laura C Alonso; Adolfo Garcia-Ocaña Journal: Diabetes Date: 2010-10-27 Impact factor: 9.461
Authors: Katja Pekrun; Gustavo De Alencastro; Qing-Jun Luo; Jun Liu; Youngjin Kim; Sean Nygaard; Feorillo Galivo; Feijie Zhang; Ren Song; Matthew R Tiffany; Jianpeng Xu; Matthias Hebrok; Markus Grompe; Mark A Kay Journal: JCI Insight Date: 2019-11-14
Authors: Min Chen; Kyungah Maeng; Akbar Nawab; Rony A Francois; Julie K Bray; Mary K Reinhard; Sanford L Boye; William W Hauswirth; Frederic J Kaye; Georgiy Aslanidi; Arun Srivastava; Maria Zajac-Kaye Journal: Hum Gene Ther Methods Date: 2017-02 Impact factor: 2.396